Literature DB >> 15732271

Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale.

M Ravnborg1, M Blinkenberg, F Sellebjerg, M Ballegaard, S Helweg Larsen, P Soelberg Sørensen.   

Abstract

The Multiple Sclerosis Impairment Scale (MSIS) is a measure of accumulated deficits assessed by means of a standard neurological examination. We compared the responsiveness of the MSIS with that of the Expanded Disability Status Scale (EDSS). We reviewed 4300 records collected systematically from 1995 to 2003 and identified 534 patients who had clinically definite multiple sclerosis and had had at least two clinical assessments with a time interval of 2-5 years. The rate of deterioration was significantly higher on the MSIS than on the EDSS. The annualized change in EDSS exhibited a maximum at baseline EDSS 4 and a subsequent rapid decline at higher baseline EDSS, while the annualized change in MSIS was fairly stable over a wide middle range of baseline MSIS. The variance of the annualized change in EDSS fluctuated markedly between the baseline EDSS categories, being highest at baseline EDSS 2, while the variance of the annualized change in MSIS was stable. The study indicates that the responsiveness of the MSIS is better than that of the EDSS in terms of both magnitude and stability over the range of measurement

Entities:  

Mesh:

Year:  2005        PMID: 15732271     DOI: 10.1191/1352458505ms1120oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  CSF inflammatory biomarkers responsive to treatment in progressive multiple sclerosis capture residual inflammation associated with axonal damage.

Authors:  Jeppe Romme Christensen; Mika Komori; Marina Rode von Essen; Rikke Ratzer; Lars Börnsen; Bibi Bielekova; Finn Sellebjerg
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

2.  Reliability and Validity of a Danish Version of the Multiple Sclerosis Neuropsychological Screening Questionnaire.

Authors:  Tobias Sejbæk; Morten Blaabjerg; Pippi Sprogøe; Mads Ravnborg
Journal:  Int J MS Care       Date:  2018 Jan-Feb

Review 3.  'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?

Authors:  H Hegen; G Bsteh; T Berger
Journal:  Eur J Neurol       Date:  2018-05-28       Impact factor: 6.089

4.  Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland.

Authors:  Elina Järvinen; Annukka Murtonen; Melina Tervomaa; Marja-Liisa Sumelahti
Journal:  Neurol Int       Date:  2019-11-29

5.  Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma.

Authors:  P Braendstrup; A R Langkilde; K Schreiber; M Ravnborg; F Sellebjerg; L Vindeløv
Journal:  Case Rep Neurol       Date:  2012-06-12

Review 6.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

7.  Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.

Authors:  Glenn A Phillips; Kathleen W Wyrwich; Shien Guo; Rossella Medori; Arman Altincatal; Linda Wagner; Jacob Elkins
Journal:  Mult Scler       Date:  2014-04-16       Impact factor: 6.312

Review 8.  Measuring Treatment Response in Progressive Multiple Sclerosis-Considerations for Adapting to an Era of Multiple Treatment Options.

Authors:  Nik Krajnc; Thomas Berger; Gabriel Bsteh
Journal:  Biomolecules       Date:  2021-09-10

9.  Creating a Real-World Data, United States Healthcare Claims-Based Adaptation of Kurtzke Functional Systems Scores for Assessing Multiple Sclerosis Severity and Progression.

Authors:  Chi T L Truong; Hoa V Le; Aaron W Kamauu; John R Holmen; Christopher L Fillmore; Monica G Kobayashi; Schiffon L Wong
Journal:  Adv Ther       Date:  2021-07-31       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.